Clinical Trial Update: Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 feasibility trial evaluating prolonged naxitamab, irinotecan, and temozolomide in relapsed or refractory neuroblastoma; the study is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Danyelza (naxitamab) (naxitamab)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Steven DuBois, MD | Conditions: Neuroblastoma, Neuroblastoma Recurrent | Phase 1 | Status: RECRUITING